The Experts in Ophthalmic Contract Research

For both in vivo and in vitro retinal disease models and retinopathy preclinical efficacy trials, Eyecro are the new state of the art. Their use of laser technology and rigorous pharmacokinetics for consistent and reliable results is nothing short of amazing. I am very impressed by their ability to study, model, and test treatments for vascular permeability of the retina, as well as issues arising from degeneration of the retina and ocular angiogenesis. This rigorous and disciplined quality lies behind their skills in formulation of eye drops, depot forming injectables, microparticles, fluorescent micro and nanoparticles, and PLGA nanoparticles, depot forming injectables, their use of FDA approved polymers to enable vitreous injection is cutting edge clinical science made real, and truly useful, taking lab results past preclinical application, and into the lives of your patients. These formulations remain in the injection site, allowing the polymer to diffuse away leaving behind a depot of the drug which slowly diffuses from depot to the retina for sustained delivery for several days. This kind of forward thinking technology is the product of rigorous study of cell cycle and apoptosis enhanced by use of flow cytometric analysis tools such as ModFit LT (Verity Software). These and other technologies take Eyecro beyond the mere formulation of lab proven compounds, and into the truly useful real world of treatment of patients for retinal and ocular disease and degeneration. My take away from all of this is that Eyecro IS the leading edge.